💊 Fármacos A-Z 🧬 Dianas 🛠 Herramientas 📚 Guías
Todos los fármacos Clases de fármacos Áreas terapéuticas Efectos Secundarios
Guías Glosario Línea de tiempo
Comparaciones Recorridos de fármacos Familias farmacológicas
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Cilastatin

CHEMBL766 Phase 4 Aprobado Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
358.5 g/mol
LogP
-1.0
Phase
4

A competitive inhibitor of the renal enzyme dehydropeptidase-I that degrades imipenem in the kidney, used exclusively in combination with imipenem to prevent renal inactivation and nephrotoxicity of the antibiotic. It has no intrinsic antibacterial activity of its own. The combination dramatically improves the pharmacokinetic profile and safety of imipenem.

Peso molecular

358,5000 g/mol

LogP

-1,00

TPSA

155,00 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Infectious Disease Ovarian Cancer Hematology Oncology Obesity Tuberculosis

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC1(C)C[C@@H]1C(=O)N/C(=C\CCCCSC[C@H](N)C(=O)O)C(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C16H26N2O5S/c1-16(2)8-10(16)13(19)18-12(15(22)23)6-4-3-5-7-24-9-11(17)14(20)21/h6,10-11H,3-5,7-9,17H2,1-2H3,(H,18,19)(H,20,21)(H,22,23)/b12-6-/t10-,11+/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C16H26N2O5S

                    

                    
                    

                        
HBD / HBA

                        
4 / 7

                    

                    
                    

                        
Enlaces Rotables

                        
11

                    

                    
                    
                    

                        
Átomos Pesados

                        
24

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Preguntas frecuentes

                

                    
                    

                        
                        

                            
A competitive inhibitor of the renal enzyme dehydropeptidase-I that degrades imipenem in the kidney, used exclusively in combination with imipenem to prevent renal inactivation and nephrotoxicity of the antibiotic. It has no intrinsic antibacterial activity of its own. The combination dramatically improves the pharmacokinetic profile and safety of imipenem.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Cilastatin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL766.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 6435415.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Aviso médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.